Get started

TASE

ESLT - Elbit Systems - Interesting long-term perspective The weekly ElliotWave (EW) chart pattern on ESLT shows rather lucrative long-term potential. Besides that we may notice fine weekly cap-and-handle formation near all time highs 80780 area. Price shows relative strength to general TASE index (shown on the liner chart above) and I like how the volume and volatility subsides in the right handle area of the chart. If the price manages to break-out above 80780 pivot with rising volume, I would consider this constructive for any position/swing longs. In more granular view, with todays gap-up open with volume already approaching yesterdays highs, it is reasonable to consider opening initial position with tight staggered 3-5% stops, with an idea to add to position if price advances to and breaks-out from the long-term pivot point mentioned above Daily
TASE:ESLTLong
by artemfedorov
NXSN/Next Vision - 2023 Rally may need to rest My ElliotWave (EW) analysis on NXSN shows that price has approached meaningful mid-term resistance zone at 2352-2627. If my technical thesis holds, price shall start digesting its 250% rally from Oct'22 bottom in near term, finishing its wave iii and starting corrective wave iv. Important and ideal EW support zone for this potential correction is 1760-1472, that coincides with advancing 200D moving average. From the trading perspective this is not exactly the area for any short selling attempt, because price has not broken even the short-term uptrend, staying above 8/21 EMAs and 50MA. One may even consider entertaining taking a long position on break out above 2400 zone with staggered 3-5% stops, although I would highly caution any attempt to trade it for the long-term move - only as a swing-trading approach (short-term), bearing in mind EW resistance zone mentioned above. The stock remains one of the strongest on TASE both technically and fundamentally. Impressive double and triple digits quarter Revenue and EBITDA growth. Any correction, followed by a base building process later this and early next year may present good investing/trading opportunities.
NShort
by artemfedorov
HUB.TA Jumps +50% in June as Global Tech Industry Slumps2022 has proven a volatile year for HUB Security investors, and not for the reasons dragging down the tech industry at large. Back in March '22, HUB (now listed on TASE) announced the closure of a SPAC agreement with RNER for a Q3/4 NASDAQ listing. After an astronomical rise to over 900ILA from ~380ILA at the start of the year, the stock took a nosedive to a YTD low of 261LA in early May. Investor jitters over the SPAC deal, the global pullback of the tech industry and stocks, and a worsening macro-economic backdrop overall were the main drivers of this see-saw motion over the past 6 months. Things are looking quite a bit greener this past month--June 2022--as HUB has regained its footing and is currently tracking a highly-encouraging uptrend. From its May 12th yearly low, HUB has climbed to over 600ILA and counting. Meanwhile, the rest of the market is getting clobbererd--as you can see, QQQ and leading cyber ETFs like CIBR and BUG are all down around 4-5% in the past month. Similarly, two of HUB's closest peers in the confidential computing sector--PANW and FTNT--are also down about 2%. Though confidential computing seems to be outperforming tech/cyber as a whole, the niche is still in the red amidst rising turbulence on global equity markets. So what is behind HUB's recovery and recent gains? I added HUB to my watchlist back in March following their SPAC deal, and have been closely watching as their SIR inched upwards MoM. HUB's SIR moved from 0.48 on May 12 to 0.84 on May 19th and then 0.82 on May 26th. That means >80% of trade volume was dominated by short activity. The company has clearly been making moves to combat malicious shorting, including the company's announcement of intention to buy back $4.5M USD worth of shares in order to force the shorts to cover. On June 9th SIR had been driven back down to 0.48, helping to explain the early-month momentum. While SIR had jumped back to 0.7 as of June 16th, it looks like the bulls had already established some upward momentum. HUB SP has increased by more than 50% in the past week alone, strongly suggesting that investors are trying to establish positions in anticipation of the value multiplier shareholders will enjoy come the NASDAQ listing. I will be interested to see how HUB's SIR looks on June 23rd, but higher-than-average trade volume and a month-long uptrend (see PVT, 30D MA shown on chart) are signs that despite the worsening economic picture on a macro-level, HUB is trading strong and girding for success on US Markets.
H
by EagleEyeAnalytics
TASE:KMDA KAMADA - is a developer of life saving therapeutics. A global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company’s strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company’s two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ("Takeda") and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasmaderived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company’s lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares. Letter from CEO (on Mar 15 2022): "Dear Shareholders, Colleagues and Business Partners: The recently completed 2021 year was a transformational period for Kamada in our path toward becoming a global leader in the plasma-derived specialty market. Following the completion of the planned manufacturing transition of Glassia® to Takeda, our recent acquisition of four FDA-approved commercial immunoglobulins and the establishment of Kamada Plasma, our U.S. based plasma collection company, we are embarking on a new and exciting chapter in the Company’s evolution. We are building on the strong foundation established over the years, entering 2022 as a "New Kamada" – a fully-integrated specialty plasma company with six FDA-approved products and strong commercial capabilities in the U.S. market, as well as a global commercial footprint in over 30 countries. Our business performed as expected in 2021 and we look ahead to 2022 for which our revenue guidance is between $125 million to $135 million, representing a 20% to 30% growth compared to 2021, with expected EBITDA margins of 12% to 15%, which would represent more than 2.5x the 2021 EBITDA. This strong guidance reflects the benefits stemmed from our new undertaken strategic direction, and the resume of revenue and profitability growth in 2022. Importantly, we further expect continued growth at a double-digit rate in the coming few years. The acquisition completed in November 2021, following a thorough search for the ideal assets for Kamada, was a critical strategic and synergistic step for the Company. The acquired products generated revenues exceeding $40 million in 2021, with over 50% gross margins, and we anticipate significantly growing the new portfolio’s revenues through proactive promotional activities in the U.S, where our newly established subsidiary, Kamada Inc., is responsible for the commercialization and direct sales of the products. We also intend to leverage our existing strong international distribution network to grow product revenue in new territories, primarily in Asia, Latin America and the Middle East. I am pleased to report that these promotional and sales activities have already commenced. Of the four acquired products, the largest is Cytogam®, indicated for the prophylaxis of cytomegalovirus disease associated with solid organs transplantation. This proprietary and unique product is the only FDA-approved IgG product for its indication. The transition of Cytogam manufacturing to our facility is already well underway, and we expect to receive FDA approval for its production at our Israeli facility by early 2023. Moreover, based on the Cytogam manufacturing transfer, expected growth of KedRAB®, our FDA-approved anti-Rabies hyperimmune product, and planned manufacturing transition of the other acquired products over the next few years, we anticipate improving the gross margins of our proprietary products by effectively utilizing our plant capacity. Another major strategic step taken is the acquisition of a plasma collection facility in Texas, in early 2021, which primarily specializes in the collection of hyper-immune plasma used for Anti-D immunoglobulin, a product manufactured by Kamada and distributed in international markets. This acquisition represented Kamada’s entry into the U.S. plasma collection market and supported our strategic goal of becoming a fully integrated specialty plasma company. We are already actively engaged in the expansion of the hyperimmune plasma collection capacity at this center and are simultaneously advancing our plan to open additional centers in the U.S. to further enhance our supply of specialty and regular plasma. KedRAB, marketed in the U.S by Kedrion, continues to gain market share in the $150 million U.S. market. During 2021 the FDA approved a label expansion for the product which differentiates KedRAB as the first and only human rabies immunoglobulin (HRIG) available in the U.S. to be clinically studied in children and confirming the safety and effectiveness of its use in pediatric population. We anticipate sales of the product to grow significantly during the next few years."
TASE:KMDA
by sequentialvzion